Bone marrow changes in chronic myelogenous leukaemia after long-term treatment with the tyrosine kinase inhibitor STI571: an immunohistochemical study on 75 patients-Reference-Cited by-同舟云学术

Bone marrow changes in chronic myelogenous leukaemia after long-term treatment with the tyrosine kinase inhibitor STI571: an immunohistochemical study on 75 patients

Published:2005-05 Issue:5 Volume:46 Page:540-550
ISSN:0309-0167
Container-title:Histopathology
language:en
Short-container-title:Histopathology

Author:

Thiele J,Kvasnicka H M,Schmitt-Graeff A,Kriener S,Engels K,Staib P,Ollig E S,Keller C,Fokkema S,Griesshammer M,Waller C F,Ottmann O G,Hansmann M L

Publisher

Wiley

Subject

General Medicine,Histology,Pathology and Forensic Medicine

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1111/j.1365-2559.2005.02119.x/fullpdf

Reference55 articles.

1. The molecular biology of chronic myeloid leukemia

2. The tyrosine kinase inhibitor STI571, like interferon-α, preferentially reduces the capacity for amplification of granulocyte-macrophage progenitors from patients with chronic myeloid leukemia

3. STI571: Targeting BCR-ABL as Therapy for CML

4. Inhibition of c-kit receptor tyrosine kinase activity by STI 571, a selective tyrosine kinase inhibitor

Cited by 15 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Morphological Changes in Bone Marrow Post Imatinib Therapy in Chronic Phase CML: A Follow up Study on Sequential Bone Marrow Aspirates and Biopsies;JOURNAL OF CLINICAL AND DIAGNOSTIC RESEARCH;2017

2. Imatinib reduces bone marrow fibrosis and overwhelms the adverse prognostic impact of reticulin formation in patients with chronic myeloid leukaemia;Journal of Clinical Pathology;2016-01-25

3. High concordance in grading reticulin fibrosis and cellularity in patients with myeloproliferative neoplasms;Modern Pathology;2014-04-25

4. BMP et cancer;médecine/sciences;2012-04

5. Chronic Myelogenous Leukemia;Current Cancer Therapy Reviews;2012-02-01